A genetic fusion between Sm14 and CTB does not reduce Schistosoma mansoni worm burden on intranasally immunized BALB/c Mice

Journal of Vaccines and Vaccination

Volumn 1, Issue 3, 2010, Pages

  Ramos, Henrique Roman ^a,b   Miyasato, Patricia Aoki ^a   Ramos, Celso Raul Romero ^c   de Mattos Arêas, Ana Paula ^d   Kawano, Toshie ^a   Ho, Paulo Lee ^a,b  

^a INSTITUTO BUTANTAN   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c INSTITUTO OSWALDO CRUZ   (Brazil)

^d UNIVERSIDADE FEDERAL DO ABC   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84858964752     PISSN: None     EISSN: 21577560     Source Type: Journal    
DOI: 10.4172/2157-7560.1000111     Document Type: Article

References (39)

1. Chitsulo L, Engels D, Montresor A, Savioli L (2000) The global status of schistosomiasis and its control. Acta Trop 77: 41-51.
2. Doenhoff MJ, Kusel JR, Coles GC, Cioli D (2002) Resistance of Schistosoma mansoni to praziquantel: is there a problem? Trans R Soc Trop Med Hyg 96: 465-469.
3. Tendler M, Brito CA, Vilar MM, Serra-Freire N, Diogo CM et al. (1996) A Schistosoma mansoni fatty acid-binding protein, Sm14, is the potential basis of a dual-purpose antihelminth vaccine. Proc Natl Acad Sci U S A 93: 269-273.
4. Angelucci F, Johnson KA, Baiocco P, Miele AE, Brunori M, et al. (2004) Schistosoma mansoni fatty acid binding protein: specificity and functional control as revealed by crystallographic structure. Biochemistry 43: 13000-13011.
5. Pertinhez TA, Sforça ML, Alves AC, Ramos CR, Ho PL, et al. (2004) 1H, 15N and 13C resonance assignments of the apo Sm14-M20(C62V) protein, a mutant of Schistosoma mansoni Sm14. J Biomol NMR 29: 553-554.
6. Ramos CR, Figueredo RC, Pertinhez TA, Vilar MM, do Nascimento AL, et al. (2003) Gene structure and M20T polymorphism of the Schistosoma mansoni Sm14 fatty acid-binding protein. Molecular, functioanl, and immunoprotection analysis. J Biol Chem 278: 12745-12751.
7. Abreu PA, Miyasato PA, Vilar MM, Dias WO, Ho PL, et al. (2004) Sm14 of Schistosoma mansoni in fusion with tetanus toxin fragment C induces immunoprotection against tetanus and schistosomiasis in mice. Infect Immun 72: 5931-5937.
8. Fonseca CT, Brito CF, Alves JB, Oliveira SC (2004) IL-12 enhances protective immunity in mice engendered by immunization with recombinant 14 kDa Schistosoma mansoni fatty acid-binding protein through an IFN-gamma and TNF-alpha dependent pathway. Vaccine 22: 503-510.
9. Fonseca CT, Pacífico LG, Barsante MM, Rassi T, Cassali GD, et al. (2006) Coadministration of plasmid expressing IL-12 with 14-kDa Schistosoma mansoni fatty acid-binding protein cDNA alters immune response profiles and fails to enhance protection induced by Sm14 DNA vaccine alone. Microbes Infect 8: 2509-2516.
10. Pacheco LG, Zucconi E, Mati VL, Garcia RM, Miyoshi A, et al. (2005) Oral administration of a live Aro attenuated Salmonella vaccine strain expressing 14-kDa Schistosoma mansoni fatty acid-binding protein induced partial protection against experimental schistosomiasis. Acta Trop 95: 132-142.
11. Varaldo PB, Leite LC, Dias WO, Miyaji EN, Torres FI, et al. (2004) Recombinant Mycobacterium bovis BCG expressing the Sm14 antigen of Schistosoma mansoni protects mice from cercarial challenge. Infect Immun 72: 3336-3343.
12. Holmgren J, Adamsson J, Anjuère F, Clemens J, Czerkinsky C, et al. (2005) Mucosal adjuvants and anti-infection and anti-immunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG DNA. Immunol Lett 97: 181-188.
13. Sun JB, Mielcarek N, Lakew M, Grzych JM, Capron A, et al. (1999) Intranasal administration of a Schistosoma mansoni glutathione S-transferasecholera toxoid conjugate vaccine evokes antiparasitic and antipathological immunity in mice. J Immunol 163: 1045-1052.
14. Lebens M, Sun JB, Sadeghi H, Bäckström M, Olsson I, et al. (2003) A mucosally administered recombinant fusion protein vaccine against schistosomiasis protecting against immunopathology and infection. Vaccine 21: 514-520.
15. Arêas AP, Oliveira ML, Ramos CR, Sbrogio-Almeida ME, Raw I, et al. (2002) Synthesis of cholera toxin B subunit gene: cloning and expression of a functional 6XHistagged protein in Escherichia coli. Protein Expr Purif 25: 481-487.
16. Ramos CR, Abreu PA, Nascimento AL, Ho PL (2004) A high-copy T7 Escherichia coli expression vector for the production of recombinant proteins with a minimal Nterminal His-tagged fusion peptide. Braz J Med Biol Res 37: 1103-1109.
17. Shapiro AL, Viñuela E, Maizel JV Jr (1967) Molecular weight estimation of polypeptide chains by electrophoresis in SDS-polyacrylamide gels. Biochem Biophys Res Commun 28: 815-820.
18. Menezes CA, Amianti J, Harayama HS, Koga PC, Trabulsi LR, et al. (2002) Inhibition of Escherichia coli heat-labile enterotoxin by neoglycoprotein and anti-lectin antibodies which mimic GM1 receptor. FEMS Microbiol Lett 216: 67-70.
19. Merritt EA, Sarfaty S, van den Akker F, L'Hoir C, Martial JA, et al. (1994) Crystal structure of cholera toxin B-pentamer bound to receptor GM1 pentasaccharide. Protein Sci 3: 166-175.
20. Bublin M, Hoflehner E, Wagner B, Radauer C, Wagner S, et al. (2007) Use of a genetic cholera toxin B subunit/allergen fusion molecule as mucosal delivery system with immunosuppressive activity against Th2 immune responses. Vaccine 25: 8395-8404.
21. Liljeqvist S, Ståhl S, Andréoni C, Binz H, Uhlén M, et al. (1997) Fusions to the cholera toxin B subunit: influence on pentamerization and GM1 binding. J Immunol Methods 210: 125-135.
22. Villella JB, Gomberg HJ, Gould SE (1961) Immunization to Schistosoma mansoni in mice inoculated with radiated cercariae. Science 134: 1073-1075.
23. Ramos CR, Vilar MM, Nascimento AL, Ho PL, Thaumaturgo N, et al. (2001) r-Sm14-pRSETA efficacy in experimental animals. Mem Inst Oswaldo Cruz 96 Suppl: 131-135.
24. Ramos CR, Spisni A, Oyama S Jr, Sforça ML, Ramos HR, et al. (2009) Stability improvement of the fatty acid binding protein Sm14 from S. mansoni by Cys replacement: structural and functional characterization of a vaccine candidate. Biochim Biophys Acta 1794: 655-662.
25. Vilar MM, Barrientos F, Almeida M, Thaumaturgo N, Simpson A, et al. (2003) An experimental bivalent peptide vaccine against schistosomiasis and fascioliasis. Vaccine 22: 137-144.
26. Tendler M, Simpson AJ (2008) The biotechnology-value chain: development of Sm14 as a schistosomiasis vaccine. Acta Trop 108: 263-266.
27. Mountford AP, Coulson PS, Wilson RA (1988) Antigen localization and the induction of resistance in mice vaccinated with irradiated cercariae of Schistosoma mansoni. Parasitology 97: 11-25.
28. Coulson PS, Wilson RA (1997) Recruitment of lymphocytes to the lung through vaccination enhances the immunity of mice exposed to irradiated schistosomes. Infect Immun 65: 42-48.
29. Arêas AP, Oliveira ML, Miyaji EN, Leite LC, Aires KA, et al. (2004) Expression and characterization of cholera toxin B-pneumococcal surface adhesin A fusion protein in Escherichia coli: ability of CTB-PsaA to induce humoral immune response in mice. Biochem Biophys Res Commun 321: 192-196.
30. Arêas AP, Oliveira ML, Miyaji EN, Leite LC, Ho PL (2005) Intradermal immunization of mice with cholera toxin B-pneumococcal surface protein A fusion protein is protective against intraperitoneal challenge with Streptococcus pneumonia. Infect Immun 73: 3810-3813.
31. Malley R, Morse SC, Leite LC, Areas AP, Ho PL, et al. (2004) Multiserotype protection of mice against pneumococcal colonization of the nasopharynx and middle nonencapsulated cells given intranasally with a nontoxic adjuvant. Infect Immun 72: 4290-4292.
32. Pimenta FC, Miyaji EN, Arêas AP, Oliveira ML, de Andrade AL, et al. (2006) Intranasal immunization with the cholera toxin B subunitpneumococcal surface antigen A fusion protein induces protection against colonization with Streptococcus pneumoniae and has negligible impact on the nasopharyngeal and oral microbiota of mice. Infect Immun 74: 4939-4944.
33. Dell K, Koesters R, Linnebacher M, Klein C, Gissmann L (2006) Intranasal immunization with human papillomavirus type 16 capsomeres in the presence of non-toxic cholera toxin-based adjuvants elicits increased vaginal immunoglobulin levels. Vaccine 24: 2238-2247.
34. Kim HJ, Kim JK, Seo SB, Lee HJ, Kim HJ (2007) Intranasal vaccination with peptides and cholera toxin subunit B as adjuvant to enhance mucosal and systemic immunity to respiratory syncytial virus. Arch Pharm Res 30: 366-371.
35. Song H, Wang Z, Zheng D, Fang W, Li Y, et al. (2005) A novel mucosal vaccine against foot-and-mouth disease virus induces protection in mice and swine. Biotechnol Lett 27: 1669-1674.
36. George Chandy A, Hultkrantz S, Raghavan S, Czerkinsky C, et al. (2006) Oral tolerance induction by mucosal administration of cholera toxin B-coupled antigen involves T-cell proliferation in vivo and is not affected by depletion of CD25+ T cells. Immunology 118: 311-320.
37. Yuki Y, Hara-Yakoyama C, Guadiz AA, Udaka S, Kiyono H, et al. (2005) Production of a recombinant cholera toxin B subunit-insulin B chain peptide hybrid protein by Brevibacillus choshinensis expression system as a nasal vaccine against autoimmune diabetes. Biotechnol Bioeng 92: 803-809.
38. Sun JB, Li BL, Lakew M, Grzych JM, Capron A, et al. (2001) Nasal administration of Schistosoma mansoni egg antigens-cholera toxin B subunit conjugate to infected mice reduces immunopathology and mortality. Adv Exp Med Biol 495: 305-309.
39. Sun JB, Stadecker MJ, Mielcarek N, Lakew M, Li BL, et al. (2001) Nasal administration of Schistosoma mansoni egg antigen-cholera B subunit conjugate suppresses hepatic granuloma formation and reduces mortality in S. mansoniinfected mice. Scand J Immunol 54: 440-447.